CoChat

ChREBP regulates fructose-induced glucose production independently of insulin signaling

Open access

The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.

Abstract

Obese, insulin-resistant states are characterized by a paradoxical pathogenic condition in which the liver appears to be selectively insulin resistant. Specifically, insulin fails to suppress glucose production, yet successfully stimulates de novo lipogenesis. The mechanisms underlying this dysregulation remain controversial. Here, we hypothesized that carbohydrate-responsive element-binding protein (ChREBP), a transcriptional activator of glycolytic and lipogenic genes, plays a central role in this paradox. Administration of fructose increased hepatic hexose-phosphate levels, activated ChREBP, and caused glucose intolerance, hyperinsulinemia, hypertriglyceridemia, and hepatic steatosis in mice. Activation of ChREBP was required for the increased expression of glycolytic and lipogenic genes as well as glucose-6-phosphatase (G6pc) that was associated with the effects of fructose administration. We found that fructose-induced G6PC activity is a major determinant of hepatic glucose production and reduces hepatic glucose-6-phosphate levels to complete a homeostatic loop. Moreover, fructose activated ChREBP and induced G6pc in the absence of Foxo1a, indicating that carbohydrate-induced activation of ChREBP and G6PC dominates over the suppressive effects of insulin to enhance glucose production. This ChREBP/G6PC signaling axis is conserved in humans. Together, these findings support a carbohydrate-mediated, ChREBP-driven mechanism that contributes to hepatic insulin resistance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci81993

Cites

70 of 70 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

5 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 70 references

Cited by

See all 212

Metadata

Authors
Kim, M.-S., Krawczyk, S. A., Doridot, L., Fowler, A. J., Wang, J. X., Trauger, S. A., Noh, H.-L., Kang, H. J., Meissen, J. K., Blatnik, M., Kim, J. K., Lai, M., & Herman, M. A.
Affiliations
  • Beth Israel Deaconess Medical Center (US)
  • Harvard University (US)
  • University of Massachusetts Chan Medical School (US)
  • Pfizer (United States) (US)
  • Broad Institute (US)
Corresponding author
Herman, Mark A.
Venue
Journal of Clinical Investigation
Published
2016-09-26
Volume
126
Issue
11
Pages
4372-4386
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W2521958286
Cited by
212
References
69
Citations by year
2026: 13 · 2025: 21 · 2024: 12 · 2023: 21 · 2022: 24 · 2021: 21 · 2020: 32 · 2019: 30 · 2018: 15 · 2017: 21 · 2016: 2
FWCI
23.10
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • eScholarship@UMassChan (submittedVersion)
Funders
  • National Institutes of Health (5u2cdk093000-11)
  • National Institute of Diabetes and Digestive and Kidney Diseases (P30DK057521, U24DK093000, U2C-DK093000, R01DK100425, K23DK083439, T32DK007516)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Keywords
ChREBP, fructose, hepatic glucose production, hepatic insulin resistance, glucose-6-phosphatase, glucose-6-phosphate, FOXO1, hepatic steatosis, hypertriglyceridemia, hyperinsulinemia, impaired glucose tolerance, de novo lipogenesis, glycolytic genes, carbohydrate metabolism
MeSH terms
Forkhead Box Protein O1, Animals, Fatty Liver, Female, Fructose, Glucose, Glucose-6-Phosphatase, Glycolysis, Humans, Insulin, Insulin Resistance, Male, Nuclear Proteins, Transcription Factors, Signal Transduction, Glucose Intolerance, Mice, Knockout, Lipogenesis, Mice, Basic Helix-Loop-Helix Leucine Zipper Transcription Factors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ChREBP regulates fructose-induced glucose production independently of insulin signaling. https://app.cochat.ai/papers/10.1172/jci81993
The paper
Kim, M.-S., Krawczyk, S. A., Doridot, L., Fowler, A. J., Wang, J. X., Trauger, S. A., Noh, H.-L., Kang, H. J., Meissen, J. K., Blatnik, M., Kim, J. K., Lai, M., & Herman, M. A. (2016). ChREBP regulates fructose-induced glucose production independently of insulin signaling. Journal of Clinical Investigation. https://doi.org/10.1172/jci81993

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.